These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34529289)

  • 21. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
    Fernandez Rivera C; Calvo Rodríguez M; Poveda JL; Pascual J; Crespo M; Gomez G; Cabello Pelegrin S; Paul J; Lauzurica R; Perez Mir M; Moreso F; Perelló M; Andres A; González E; Fernandez A; Mendiluce A; Fernández Carbajo B; Sanchez Fructuoso A; Calvo N; Suarez A; Bernal Blanco G; Osuna A; Ruiz-Fuentes MC; Melilli E; Montero Perez N; Ramos A; Fernández B; López V; Hernandez D;
    Clin Transplant; 2022 Mar; 36(3):e14550. PubMed ID: 34851532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Envarsus XR® pharmacokinetics in adolescents post-kidney transplantation - A pilot study.
    ElChaki R; Ettenger R; Lee S; Chen L; Gales B; Srivastava R; Pearl M
    Pediatr Transplant; 2023 May; 27(3):e14480. PubMed ID: 36732080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of LCP-Tacrolimus (Envarsus XR) in simultaneous pancreas and kidney (SPK) transplant recipients.
    Torabi J; Konicki A; Rocca JP; Ajaimy M; Campbell A; Azzi Y; Pynadath C; Liriano-Ward L; Akalin E; Kinkhabwala M; Graham JA
    Am J Surg; 2020 Apr; 219(4):583-586. PubMed ID: 32122660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
    Vondrak K; Parisi F; Dhawan A; Grenda R; Webb NJA; Marks SD; Debray D; Holt RCL; Lachaux A; Kelly D; Kazeem G; Undre N
    Clin Transplant; 2019 Oct; 33(10):e13698. PubMed ID: 31436896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of once-daily LCP-Tacrolimus with adolescent and young adult solid organ transplant recipients.
    Householder S; Ramakrishnan A; Chen JK; Gorsch L; Tsapepas D; Lobritto S; Rundle A; Vittorio JM
    Pediatr Transplant; 2024 Jun; 28(4):e14777. PubMed ID: 38702932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended-release tacrolimus: a review of its use in de novo kidney transplantation.
    McCormack PL
    Drugs; 2014 Nov; 74(17):2053-64. PubMed ID: 25352392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.
    Rubik J; Debray D; Kelly D; Iserin F; Webb NJA; Czubkowski P; Vondrak K; Sellier-Leclerc AL; Rivet C; Riva S; Tönshoff B; D'Antiga L; Marks SD; Reding R; Kazeem G; Undre N
    Transpl Int; 2019 Nov; 32(11):1182-1193. PubMed ID: 31325368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended-Release Once-Daily Tacrolimus Tablets.
    Philosophe B; Leca N; West-Thielke PM; Horwedel T; Culkin-Gemmell C; Kistler K; Stevens DR
    J Clin Pharmacol; 2018 Jul; 58(7):891-896. PubMed ID: 29462506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients.
    Gaber AO; Alloway RR; Bodziak K; Kaplan B; Bunnapradist S
    Transplantation; 2013 Jul; 96(2):191-7. PubMed ID: 23715050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations.
    Henin E; Govoni M; Cella M; Laveille C; Piotti G
    Adv Ther; 2021 Oct; 38(10):5317-5332. PubMed ID: 34515977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers.
    Alloway RR; Trofe-Clark J; Brennan DC; Kerr J; Cohen EA; Meier-Kriesche U; Stevens DR; Moten MA; Momper JD
    Ther Drug Monit; 2020 Oct; 42(5):679-685. PubMed ID: 32453306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Multi-Centre Non-Interventional Study to Assess the Tolerability and Effectiveness of Extended-Release Tacrolimus (LCPT) in De Novo Liver Transplant Patients.
    Soliman T; Gyoeri G; Salat A; Mejzlík V; Berlakovich G
    J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study.
    Langone A; Steinberg SM; Gedaly R; Chan LK; Shah T; Sethi KD; Nigro V; Morgan JC;
    Clin Transplant; 2015 Sep; 29(9):796-805. PubMed ID: 26113208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of a novel tablet formulation of tacrolimus and conventional capsule formulation in
    Liu Z; Yin K; Liu H; Wang N; Yao J; Zhou J; Tang Y; Yin Z
    Front Pharmacol; 2023; 14():1310339. PubMed ID: 38143499
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-life comparison of efficacy and safety profiles of two prolonged-release tacrolimus formulations in de novo kidney transplant recipients: 24 months of follow-up.
    Czarnecka P; Czarnecka K; Baczkowska T; Lagiewska B; Durlik M
    PLoS One; 2023; 18(1):e0278894. PubMed ID: 36662740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study.
    Shin MH; Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Yun YI; Kim WJ; Kang WH; Kim SH; Jiang H; Lee S; Tak EY
    Clin Transplant; 2018 Sep; 32(9):e13376. PubMed ID: 30098071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients.
    Wöhl DS; James B; Götz M; Brennfleck F; Holub-Hayles I; Mutzbauer I; Baccar S; Brunner SM; Geissler EK; Schlitt HJ;
    Trials; 2023 May; 24(1):325. PubMed ID: 37170284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion From Immediate-Release to Prolonged-Release Tacrolimus in Kidney Transplant Patients With Tremor: A Case Series Study.
    Kamińska D; Hożejowski R; Chamienia A; Dębska-Ślizień A; Idasiak-Piechocka I; Oko A; Baranowicz-Gąszczyk I; Załuska W; Mazanowska O; Krajewska M
    Transplant Proc; 2024 May; 56(4):776-780. PubMed ID: 38453593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.